BRIDGEWATER, N.J., June 4, 2020 /CNW/ -- Bausch + Lomb, a
leading global eye health business of Bausch Health Companies
Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that it has
received 510(k) clearance from the U.S. Food and Drug
Administration (FDA) for BAUSCH + LOMB INFUSE™ daily disposable
silicone hydrogel (SiHy daily) contact lenses.
BAUSCH + LOMB INFUSE contact lenses feature a next generation
contact lens material (kalifilcon A), which is designed to meet the
unmet needs of contact lens wearers, including those who experience
contact lens dryness. Engineered with Bausch + Lomb's most advanced
proprietary contact lens technologies, BAUSCH + LOMB INFUSE offers
outstanding breathability for healthy lens wear while providing
exceptional all-day comfort and high definition optics.
"Bausch + Lomb continues to push the innovation curve in the
contact lens space with the FDA's clearance of BAUSCH + LOMB
INFUSE," said Joe Gordon, U.S.
president, Bausch + Lomb. "We are excited to add this breakthrough
new SiHy daily contact lens to our portfolio and provide the
outstanding health, vision and comfort that practitioners expect
and patients deserve from Bausch + Lomb. We anticipate BAUSCH +
LOMB INFUSE will be available to eye care practitioners in the
second half of 2020."
About Bausch + Lomb
Bausch + Lomb, a leading global
eye health business of Bausch Health Companies Inc., is solely
focused on helping people see. Its core businesses include
over-the-counter products, dietary supplements, eye care products,
ophthalmic pharmaceuticals, contact lenses, lens care products,
ophthalmic surgical devices and instruments. Bausch + Lomb
develops, manufactures and markets one of the most comprehensive
product portfolios in the industry, which is available in more than
100 countries. For more information, visit www.bausch.com.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could," "would," "may,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties discussed in Bausch
Health's most recent annual report on Form 10-K and detailed from
time to time in Bausch Health's other filings with the U.S.
Securities and Exchange Commission and the Canadian Securities
Administrators, which factors are incorporated herein by reference.
They also include, but are not limited to, risks and uncertainties
caused by or relating to the evolving COVID-19 pandemic, and the
fear of that pandemic and its potential effects, the severity,
duration and future impact of which are highly uncertain and cannot
be predicted, and which may have a material adverse impact on
Bausch Health, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
®/TM are trademarks of Bausch & Lomb Incorporated or its
affiliates.
© 2020 Bausch & Lomb Incorporated or its
affiliates.
INF.0043.USA.20
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/fda-provides-510k-clearance-for-bausch--lomb-infuse-daily-disposable-silicone-hydrogel-sihy-daily-contact-lenses-301070542.html
SOURCE Bausch Health Companies Inc.